Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.

A disease-oriented trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide) given once every 3 weeks was undertaken in patients with advanced non-Hodgkin's lymphoma. None of 15 adequately treated patients achieved complete or partial remissions. Toxicity was mild-to-moderate, consisting of myelosuppression (principally granulocytopenia) and malaise. The lack of any major responses in this number of patients suggests that, in this schedule, the drug is not useful in therapy for advanced non-Hodgkin's lymphoma.